SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Resectable NSCLCSeptember 19, 2026

Spread through air spaces carried an HR of 2.32 for DFS in stage 1 lung adenocarcinoma

Spread through air spaces was present in 54.2% of 378 stage 1 lung adenocarcinomas and carried an adjusted hazard ratio of 2.32 for disease-free survival, in a British Journal of Cancer study pairing whole exome and RNA sequencing with the histology. STAS entered the ninth edition of the TNM staging system as an adverse histologic feature, and the molecular features underlying it remain incompletely characterised.
Share

In brief

  • Among 378 patients with stage 1 lung adenocarcinoma and known status for spread through air spaces (STAS), 54.2% had STAS-positive tumours, at a similar rate in EGFR-mutant and EGFR-wildtype disease.
  • STAS remained independently associated with inferior disease-free survival after multivariable adjustment, with a hazard ratio of 2.32 (95% CI 1.16 to 4.63; p = 0.017).
  • STAS-positive tumours were significantly associated with stage 1B disease, lymphovascular invasion, higher histological grade, micropapillary or solid predominant subtype and a PD-L1 tumour proportion score of 1% or above.
  • On whole exome and RNA sequencing they were enriched for TP53 co-mutations, whole genome doubling, non-TRU transcriptomic subtypes and upregulated cell cycle pathways.
  • Those molecular findings pointed the same way in EGFR-mutant and in EGFR-wildtype tumours.

Study at a glance

  • Cohort: 378 patients with stage 1 lung adenocarcinoma and known STAS status
  • STAS incidence: 54.2%, similar in EGFR-mutant and EGFR-wildtype tumours
  • Methods: Whole exome and RNA sequencing of tumour samples with matched normal controls; disease-free survival by Kaplan-Meier method and Cox regression
  • Survival: Hazard ratio 2.32 (95% CI 1.16 to 4.63; p = 0.017) after multivariable adjustment
  • Histologic associations: Stage 1B disease, lymphovascular invasion, higher histological grade, micropapillary or solid predominant subtype, PD-L1 tumour proportion score 1% or above
  • Molecular findings: TP53 co-mutations, whole genome doubling, non-TRU transcriptomic subtypes, upregulated cell cycle pathways
  • Not reported: Overall survival and the duration of follow-up, neither of which appears in the published abstract

An adjusted hazard ratio of 2.32, on a feature present in over half the cohort

Just over half of these stage 1 tumours carried STAS, which makes it common rather than a marker of an unusual subset. Its incidence was much the same whether or not the tumour carried an EGFR mutation. It also travelled with stage 1B disease, lymphovascular invasion, higher grade, micropapillary or solid predominant subtype and a PD-L1 tumour proportion score of 1% or above, each reported as significant.

After multivariable adjustment STAS still stood on its own, with a confidence interval from 1.16 to 4.63. That interval spans a fourfold range, so the direction of the association is established while its size is not. The abstract does not name the covariates the model adjusted for, which a reader would need to judge how much of the histologic company STAS keeps is already in the estimate.

TP53 co-mutations, whole genome doubling and cell cycle upregulation

The sequencing found enrichment for TP53 co-mutations and whole genome doubling, with non-TRU transcriptomic subtypes and upregulation of cell cycle-related pathways, pointing the same way in EGFR-mutant and EGFR-wildtype tumours. In the authors’ reading those features amount to genomic instability and cell cycle dysregulation.

“STAS+ in stage 1 LUAD is associated with a distinct molecular phenotype characterised by genomic instability and cell cycle dysregulation, consistent with a more aggressive biological phenotype with implications for risk stratification and adjuvant therapy selection.”Saw et al., British Journal of Cancer (2026)

That conclusion is about which patients to pick out, and nothing here tests a treatment. No adjuvant regimen was given or compared, and no second cohort checked the molecular findings, so the work supports treating STAS as a marker worth stratifying on rather than a rule for who gets adjuvant therapy.

Sources

  1. British Journal of Cancer. Genomic and transcriptomic landscape of spread through air spaces in stage 1 lung adenocarcinoma (2026-09-19). doi.org

Featuring Lung Summit faculty

This study was co-authored by Lung Summit faculty Stephanie Saw.

This article was produced independently by the Lung Summit editorial team, without industry funding or input.

i 3 On This Page

Share

       Continue With

Related Topics

Videos
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Nov 13 2026
ILCS 2026
Advanced NSCLCResectable NSCLCSCLC

Panel: open questions & patient cases

Nov 13 2026
ILCS 2026
Resectable NSCLCImmunotherapies

Latest options in early-stage NSCLC: novel IO approaches for improved outcomes

S. Patel
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCResectable NSCLCTargeted Therapies

One Backbone, Many Opportunities: Osimertinib Across the EGFRm NSCLC Journey

M. Hochmair
Prof. Martin Reck
Nov 04 2026
SPONSORED EXPERT TALK
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck
Patient Cases
Oct 04 2024
ILCS 2024
Advanced NSCLCResectable NSCLC

Patient Cases & Open Questions

} 32 min

Nuria Maria Novoa
Oct 04 2024
ILCS 2024
Resectable NSCLC

Surgical Dilemmas: Defining Resectability for Optimal Patient Outcomes in the IO Era

} 27 min

N. Novoa
Nov 13 2026
ILCS 2026
SCLC

Debate: which is the better choice in 1L ES-SCLC?

G. MountziosA. Dingemans
Nov 13 2026
ILCS 2026
SCLC

The emerging role of T-cell engagers and ADCs in SCLC

N. Frost
Nov 13 2026
ILCS 2026
Advanced NSCLC

New compounds and combinations for non-oncogene-addicted advanced NSCLC

A. Cortellini
Nov 13 2026
INDUSTRY SYMPOSIUM
Advanced NSCLCTargeted Therapies

First-Line NSCLC in Transition: Opportunities and Challenges for KRAS G12C

A. Curioni-Fontecedro
Nov 13 2026
ILCS 2026
Advanced NSCLCADCs

The ADC wave: integrating new agents in NSCLC

D. Planchard
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Targeting (K)RAS with new compounds

C. Lovly
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

Other actionable genomic alterations, incl. HER2 and ROS1

T. Sequeira
Nov 13 2026
ILCS 2026
Advanced NSCLCTargeted Therapies

New standards in EGFR- and ALK-positive NSCLC

H. Horinouchi
Nov 13 2026
ILCS 2026
Biomarkers

ctDNA-guided decisions in lung cancer: ready or not?

M. Das
Nov 13 2026
ILCS 2026

Welcome & introduction

S. PetersA. Addeo
Dr. Jacob Sands
Nov 04 2026
SPONSORED INTERVIEW
SCLCImmunotherapies

New Therapy Options in SCLC and AE Management

Dr. Jacob Sands discusses new treatment options in small cell lung cancer and the management of their adverse events in this on-demand expert interview.

J. Sands
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oliver Gautschi on EGFR+ NSCLC
Jul 20 2026
SPONSORED INTERVIEW
Advanced NSCLCTargeted Therapies

Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi

Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.

O. Gautschi
Articles
Nov 16 2026
RESEARCH
Advanced NSCLCResectable NSCLC

South Asian experts agree consensus recommendations for NSCLC, with low-cost options built in

V. Noronha
Nikolaj Frost
Nov 15 2026
RESEARCH
Advanced NSCLCResectable NSCLC

A 454-patient single-cell atlas links NSCLC tumour cell states to metastasis and survival

N. Frost
Nov 12 2026
RESEARCH
BiomarkersResectable NSCLCTargeted Therapies

MTAP loss seen in 17% of NSCLC by immunohistochemistry, with PRMT5 inhibitors active in TKI-resistant cells

Z. Piotrowska
Nikolaj Frost
Oct 31 2026
RESEARCH
Resectable NSCLCImmunotherapies

KEYNOTE-867 tested pembrolizumab with SBRT in unresected stage I or II NSCLC

N. Frost
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

M. ReckN. GirardA. Filippi
Oct 29 2026
RESEARCH
BiomarkersResectable NSCLCImmunotherapies

Early ctDNA clearance was associated with longer event-free survival in resectable NSCLC in NeoCOAST-2

T. CasconeP. Forde
Oct 26 2026
INDUSTRY NEWS
Advanced NSCLCResectable NSCLCTargeted Therapies

Divarasib extended OS over sotorasib or adagrasib in previously treated KRAS G12C-mutated NSCLC

Oct 21 2026
RESEARCH
Advanced NSCLCBiomarkersResectable NSCLC

ctDNA on immunotherapy is prognostic across NSCLC stages, but ctDNA-guided treatment remains investigational

U. Malapelle
Oct 15 2026
NEWS
Resectable NSCLC

A papal diagnosis turns the world’s attention to its most diagnosed cancer

Oct 14 2026
RESEARCH
Resectable NSCLC

More lymph nodes examined at segmentectomy tracked with longer survival in early-stage NSCLC

J. Perentes
Oct 03 2026
RESEARCH
Advanced NSCLCResectable NSCLCTargeted Therapies

AI-extracted records describe stage I–III NSCLC care at four Spanish hospitals before immunotherapy

A. Calles
Sep 30 2026
RESEARCH
Resectable NSCLC

Spread through air spaces predicted relapse after both lobectomy and segmentectomy in JCOG0802 stage IA NSCLC

S. BerezowskaL. BubendorfP. Hofman
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

M. ReckM. Hochmair
Sep 25 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Multi-omic profiling separated recurrence risk within pathological stage in resected EGFR-mutant lung adenocarcinoma

S. Saw
Sep 17 2026
CONGRESS
Resectable NSCLCTargeted Therapies

Adjuvant osimertinib reduced the risk of death by 47% at eight years in ADAURA

Sep 15 2026
CONGRESS
Advanced NSCLCBiomarkersResectable NSCLC

WCLC 2026, day 4: tumour budding, BRAF class II and III, brain radiotherapy timing, and mobile CT screening

Sep 14 2026
CONGRESS
Resectable NSCLCTargeted Therapies

ADAURA at eight years: adjuvant osimertinib keeps a 15-point overall survival lead

Sep 14 2026
CONGRESS
Advanced NSCLCResectable NSCLCADCs

WCLC 2026, day 3: EGFR exon 20, ROS1 and HER2 in advanced NSCLC, and 79% alive at eight years after surgery

Sep 12 2026
CONGRESS
Advanced NSCLCResectable NSCLCSCLC

WCLC 2026, day 1: extended-interval and subcutaneous dosing in SCLC, and a 70% early response

Aug 31 2026
RESEARCH
Resectable NSCLCTargeted Therapies

Adjuvant alectinib held its advantage in ALINA’s Asia subgroup, on 31 events and immature survival data

H. Horinouchi